山外山(688410) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥189,262,367.90, representing a 16.77% increase compared to ¥162,081,904.07 in the same period last year[6] - Net profit attributable to shareholders was ¥37,006,398.74, an increase of 8.10% from ¥34,232,483.34 year-on-year[6] - The company reported a basic and diluted earnings per share of ¥0.1162, a 9.11% increase from ¥0.1065 in the previous year[6] - Total operating revenue for Q1 2025 reached ¥189,262,367.90, a 16.77% increase from ¥162,081,904.07 in Q1 2024[21] - Net profit for Q1 2025 was ¥36,905,077.50, representing an increase of 9.86% compared to ¥33,575,271.86 in Q1 2024[22] - Basic and diluted earnings per share for Q1 2025 were both ¥0.1162, up from ¥0.1065 in Q1 2024[23] Cash Flow - The net cash flow from operating activities surged to ¥15,428,603.44, a significant increase of 4,614.07% compared to ¥327,288.28 in the previous year[6] - Cash flow from operating activities for Q1 2025 was ¥15,428,603.44, significantly higher than ¥327,288.28 in Q1 2024[26] - Cash inflow from operating activities totaled ¥193,040,465.61 in Q1 2025, compared to ¥133,181,171.98 in Q1 2024[25] - The ending cash and cash equivalents balance for Q1 2025 was ¥619,009,413.63, down from ¥702,935,710.65 in Q1 2024[26] Expenses and Costs - Research and development expenses totaled ¥16,427,143.12, marking a 32.20% increase from ¥12,425,971.75 in the same period last year, accounting for 8.68% of total revenue[6] - Total operating costs for Q1 2025 were ¥153,931,158.16, up 14.29% from ¥134,689,255.37 in Q1 2024[21] - The company reported a tax expense of ¥3,791,523.32 for Q1 2025, compared to ¥2,654,692.42 in Q1 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,042,520,476.59, reflecting a 1.54% increase from ¥2,011,555,609.34 at the end of the previous year[6] - The company's total assets amounted to CNY 2,042,520,476.59, an increase from CNY 2,011,555,609.34 as of December 31, 2024, reflecting a growth of approximately 1.1%[17][20] - The company's total liabilities decreased to CNY 323,092,480.13 from CNY 333,259,232.90, representing a reduction of about 3.5%[19] - The total equity attributable to the parent company increased to CNY 1,728,293,337.34 from CNY 1,687,060,396.08, marking a growth of approximately 2.5%[20] - Cash and cash equivalents decreased to CNY 559,354,161.05 from CNY 631,440,099.36, a decline of about 11.4%[17] - The company's accounts receivable rose to CNY 117,865,716.06 from CNY 104,292,725.45, indicating an increase of approximately 13.1%[17] - Inventory levels decreased to CNY 144,847,089.77 from CNY 152,969,747.46, a decline of about 5.3%[17] - The company reported a total of CNY 1,682,142,200.16 in current assets, slightly up from CNY 1,678,045,417.97, reflecting a marginal increase of about 0.2%[18] - The non-current assets increased to CNY 360,378,276.43 from CNY 333,510,191.37, showing a growth of approximately 8.1%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,938[12] - The top shareholder, Gao Guangyong, holds 24.26% of the shares, totaling 77,961,620 shares[12] Market Position - The company attributed the revenue growth to its leading position in the domestic blood purification equipment market and increased sales of self-produced consumables[11] Other Information - The company's short-term borrowings and other liabilities were not specified, indicating a focus on maintaining liquidity and managing debt levels[19] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[15]